Assembly Biosciences Inc (ASMB) Given Average Recommendation of “Buy” by Brokerages

Assembly Biosciences Inc (NASDAQ:ASMB) has been given a consensus rating of “Buy” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $40.67.

ASMB has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Wednesday, November 15th. Jefferies Group initiated coverage on shares of Assembly Biosciences in a research report on Wednesday, November 8th. They set a “buy” rating and a $50.00 price objective on the stock. BidaskClub cut shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. ValuEngine cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th.

In related news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $33.70, for a total value of $33,700.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 4,000 shares of company stock worth $157,660. 19.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC lifted its position in Assembly Biosciences by 13.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 1,203 shares in the last quarter. California Public Employees Retirement System lifted its position in Assembly Biosciences by 13.8% in the 3rd quarter. California Public Employees Retirement System now owns 27,925 shares of the biopharmaceutical company’s stock valued at $975,000 after acquiring an additional 3,385 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Assembly Biosciences by 10.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 47,317 shares of the biopharmaceutical company’s stock valued at $1,653,000 after acquiring an additional 4,330 shares in the last quarter. Nationwide Fund Advisors bought a new position in Assembly Biosciences in the 2nd quarter valued at about $161,000. Finally, Strs Ohio lifted its position in Assembly Biosciences by 66.9% in the 3rd quarter. Strs Ohio now owns 22,700 shares of the biopharmaceutical company’s stock valued at $792,000 after acquiring an additional 9,100 shares in the last quarter. 62.00% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences (ASMB) traded down $0.84 during mid-day trading on Friday, hitting $44.91. 84,400 shares of the stock were exchanged, compared to its average volume of 103,967. The company has a market cap of $781.33, a PE ratio of -15.12 and a beta of 0.90. Assembly Biosciences has a one year low of $12.15 and a one year high of $52.37.

TRADEMARK VIOLATION NOTICE: This report was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://transcriptdaily.com/2018/01/05/assembly-biosciences-inc-asmb-given-average-recommendation-of-buy-by-brokerages.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply